Export Mendeley
＜journal article＞
Effect of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice
| Creator | |
|---|---|
| Language | |
| Publisher | |
| Date | |
| Source Title | |
| Vol | |
| Issue | |
| First Page | |
| Last Page | |
| Publication Type | |
| Access Rights | |
| Rights | |
| Rights | |
| Related DOI | |
| Related URI | |
| Related HDL | |
| Abstract | BACKGROUND: Lipodystrophies are rare acquired and genetic disorders characterized by the complete or partial absence of body fat with a line of metabolic disorders. Previous studies demonstrated that d...ietary conjugated linoleic acid (CLA) induces hepatic steatosis and hyperinsulinemia through the drastic reduction of adipocytokine levels due to a paucity of adipose tissue in mice and the pathogenesis of these metabolic abnormalities in CLA-fed mice is similar to that in human lipodystrophy. The present study explores the effect of leptin infusion on the pathogenesis of diet-induced lipodystrophy in mice. C57BL/6N mice were assigned to three groups: (1) mice were fed a semisynthetic diet supplemented with 6% corn oil and infused PBS intraperitoneally (normal group), (2) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused PBS intraperitoneally (lipodystrophy-control group), and (3) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused recombinant murine leptin intraperitoneally (lipodystrophy-leptin group). All mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day from third week of the feeding period for 1 week. RESULTS: The results indicate that leptin infusion can attenuate hepatic steatosis and hyperinsulinemia through the reduction of hepatic triglyceride synthesis and the improvement of insulin sensitivity in diet-induced lipodystrophy model mice. CONCLUSION: We expect the use of this model for clarifying the pathophysiology of lipodystrophy-induced metabolic abnormalities and evaluating the efficacy and safety of drug and dietary treatment.show more |
Hide fulltext details.
| File | FileType | Size | Views | Description |
|---|---|---|---|---|
1958381
|
324 KB | 259 |
Details
| EISSN | |
|---|---|
| NCID | |
| Record ID | |
| Related PubMed ID | |
| Subject Terms | |
| Created Date | 2018.10.26 |
| Modified Date | 2023.11.27 |